Syfovre was approved for GA in the US last year ... Neuraxpharm and partner Minoryx Therapeutics, meanwhile, were unable to convince the CHMP that they should get conditional approval for PPAR ...

Four months after the Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the ...

Syfovre was approved for the treatment of geographic ... Apellis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency confirmed its June ...

While the company’s topline expanded ~78% to $196.8M, it still missed Wall Street forecasts by $2.99M as Syfovre net product revenue from the U.S. fell unexpectedly. The newly launched drug for ...

While Syfovre’s revenue miss is no doubt disappointing, the drug remained the market leader in GA with more than 88,500 doses delivered to physicians in the third quarter, Apellis said in its ...

a large Medicare Advantage plan will make SYFOVRE the only preferred product on its formulary. Received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP ...

The company’s drug, Syfovre, experienced a slight decline in sales for Q3, primarily due to increased gross-to-net adjustments that affected revenue, despite a 7% increase in commercial vial ...

Importantly, we continue to believe SYFOVRE remains on track to becoming a blockbuster drug. Quickly touching on Europe. We were disappointed with the negative CHMP opinion despite multiple ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

Syfovre Product Revenue ... Apellis Pharmaceuticals Inc (NASDAQ:APLS) faced a negative CHMP opinion in Europe, leading to a decision not to pursue EU approval further. The company anticipates ...